Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

These two phase 3 studies show the efficacy of canakinumab in systemic JIA with active systemic features. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT00889863 and NCT00886769.).